SCHEDULE 13G/A
0001943462-24-000004
0001943462
XXXXXXXX
LIVE
2
Common Stock, $0.001 par value
12/13/2024
0001583648
PALVELLA THERAPEUTICS, INC.
697947109
125 STRAFFORD AVE
WAYNE
PA
19087
Rule 13d-1(b)
Dellora Investments Master Fund LP
E9
0.00
123034.00
0.00
123034.00
123034.00
1.1
PN
Dellora Investments LP
DE
0.00
141079.00
0.00
141079.00
141079.00
1.3
IA
HC
Kevin Pyun
X1
0.00
141079.00
0.00
141079.00
141079.00
1.3
IN
HC
PALVELLA THERAPEUTICS, INC.
125 STRAFFORD AVE, WAYNE, PENNSYLVANIA, 19087
Dellora Investments Master Fund LP
Dellora Investments LP
Kevin Pyun
Dellora Investments Master Fund LP
c/o Dellora Investments LP
283 Greenwich Avenue, 3rd floor
Greenwich, CT 06830
Dellora Investments LP
283 Greenwich Avenue, 3rd floor
Greenwich, CT 06830
Kevin Pyun
c/o Dellora Investments LP
283 Greenwich Avenue, 3rd floor
Greenwich, CT 06830
Dellora Investments Master Fund LP - Cayman Islands
Dellora Investments LP - Delaware
Kevin Pyun - United States
N
IA
HC
Dellora Investments LP is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. Dellora Investments LP, which serves as investment adviser to private funds, including but not limited to Dellora Investments Master Fund, LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Mr. Pyun, as Principal of Dellora Investments LP, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Dellora Investments LP and Mr. Pyun expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Dellora Investments LP or Mr. Pyun are the beneficial owner of any of the securities reported herein.
Dellora Investments Master Fund LP - 123,034
Dellora Investments LP - 141,079
Kevin Pyun - 141,079
Palvella Therapeutics, Inc. is the the successor to Pieris Pharmaceuticals, Inc. After the closing of the merger and financing on December 13, 2024, Dellora Investments LP no longer holds greater than 5% in the reporting company.
Ownership percentage is based on 11,211,203 shares of common stock outstanding as of December 13, 2024, as represented by the Issuer in the Form 8-K filed with the Securities and Exchange Commission on December 16, 2024.
Dellora Investments Master Fund LP - 1.1%
Dellora Investments LP - 1.3%
Kevin Pyun - 1.3
Dellora Investments Master Fund LP - 0
Dellora Investments LP - 0
Kevin Pyun - 0
Dellora Investments Master Fund LP - 123,034
Dellora Investments LP - 141,079
Kevin Pyun - 141,079
Dellora Investments Master Fund LP - 0
Dellora Investments LP - 0
Kevin Pyun - 0
Dellora Investments Master Fund LP - 123,034
Dellora Investments LP - 141,079
Kevin Pyun - 141,079
Y
Y
N
See note above
Y
Y
N
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Dellora Investments Master Fund LP
/s/ Kevin Pyun
12/17/2024
Dellora Investments LP
/s/ Kevin Pyun
12/17/2024
Kevin Pyun
/s/ Kevin Pyun
12/17/2024